Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Somatostatinoma × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 73 Neoplasm Metastasis 6 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Neoplasms 3 Ovarian Neoplasms 2 Melanoma 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Untreated Operable Early Breast Cancer 1 Testicular Neoplasms 1 Teratoma 1 Somatostatinoma 1 Solid Tumors 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Squamous Cell Lung Carcinoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Patient Acceptance of Health Care 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1

Interventions

Capecitabine 3 Trastuzumab 2 Temozolomide 2 Sunitinib 2 Octreotide 2 Leucovorin 2 Everolimus 2 Bevacizumab 2 vatalanib 1 tipifarnib 1 temsirolimus 1 sapanisertib 1 regorafenib 1 pentetreotide 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 gallium Ga 68 dotatate 1 cixutumumab 1 batifiban 1 aflibercept 1 Thalidomide 1 Streptozocin 1 Sirolimus 1 Salts 1 Oxaliplatin 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02806648 2018-01-23

PALBONET

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡